EP Wealth Advisors LLC Purchases Shares of 7,012 Omnicell, Inc. $OMCL

EP Wealth Advisors LLC purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 7,012 shares of the company’s stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors have also made changes to their positions in OMCL. Jane Street Group LLC boosted its stake in shares of Omnicell by 7.4% in the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock valued at $2,417,000 after purchasing an additional 3,725 shares during the period. Deutsche Bank AG lifted its stake in Omnicell by 23.0% in the fourth quarter. Deutsche Bank AG now owns 52,493 shares of the company’s stock worth $2,337,000 after acquiring an additional 9,822 shares during the last quarter. Lazard Asset Management LLC lifted its stake in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after acquiring an additional 737,536 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new position in Omnicell in the fourth quarter worth approximately $286,000. Finally, Nomura Holdings Inc. lifted its stake in Omnicell by 85.0% in the fourth quarter. Nomura Holdings Inc. now owns 106,463 shares of the company’s stock worth $4,740,000 after acquiring an additional 48,906 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL opened at $32.77 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The stock has a market capitalization of $1.51 billion, a P/E ratio of 65.54, a P/E/G ratio of 7.06 and a beta of 0.82. The company’s fifty day moving average is $30.55 and its two-hundred day moving average is $31.21. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analysts’ expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of recent research reports. Bank of America lifted their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd. Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 11th. Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company boosted their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, July 21st. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.